# A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

> **NCT06650514** · PHASE2 · RECRUITING · sponsor: **Vall d'Hebron Institute of Oncology** · enrollment: 10 (estimated)

## Conditions studied

- Osteosarcoma
- Osteosarcoma in Children

## Interventions

- **DRUG:** OMO-103

## Key facts

- **NCT ID:** NCT06650514
- **Lead sponsor:** Vall d'Hebron Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-27
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-01-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06650514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06650514, "A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06650514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*